Re: A pilot study of the tolerability of two BCG maintenance regimens in the treatment of high risk superficial bladder cancer

摘要

We read with interest the recent article by Gilmore et al. [1], detailing their experience with alternative BCG regimens for high risk bladder cancer. We note their finding of equivalent tolerability for a single dose regimen, with similar cancer outcomes.We too have used a reduced dose maintenance regimen for some patients in our unit for some time. In a recent departmental review we identified 52 patients completing a maintenance BCG program. 33 patients received singlet (1 x 81 mg instillations), and 19 triplet (3x 81 mg) maintenance regimens. The decision to use a singlet regimen was based on consultant preference or poor tolerance of standard induction doses. The mean age of our patients was 70.6 years, with no significant difference between the groups.